Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2017

Open Access 01-12-2017 | Research article

Dynamic changes of paraoxonase 1 activity towards paroxon and phenyl acetate during coronary artery surgery

Authors: Anna Wysocka, Marek Cybulski, Henryk Berbeć, Andrzej Wysokiński, Janusz Stążka, Jadwiga Daniluk, Tomasz Zapolski

Published in: BMC Cardiovascular Disorders | Issue 1/2017

Login to get access

Abstract

Background

Serum paraoxonase 1 (PON1), an enzyme associated with high – density lipoproteins (HDL) particles, inhibits the oxidation of serum lipoproteins and cell membranes. PON1 activity is lower in patients with atherosclerosis and in inflammatory diseases. The systemic inflammatory response provoked during cardiopulmonary bypass grafting may contribute to the development of postoperative complications. The aim of the present study was to estimate the dynamic changes in paraoxonase 1 (PON1) activity towards paraoxon and phenyl acetate during and after coronary artery surgery.

Methods

Twenty six patients with coronary heart disease undergoing coronary artery bypass grafting (CABG) were enrolled into the study. Venous blood samples were obtained preoperatively, after aortic clumping, after the end of operation, at 6, 18, 30 and 48 h after operation. Paraoxonase activity was measured spectrophotometrically in 50 mM glycine/NaOH buffer (pH 10.5) containing 1.0 mM paraoxon, and 1.0 mM CaCl2. Arylesterase activity was measured in 20 mM TrisCl buffer (pH 8.0) containing 1 mM phenyl acetate and 1 mM CaCl2.

Results

PON1 activity toward paraoxon and phenyl acetate significantly decreased after aorta cross clumping and increased directly after operation. PON1 activity towards paraoxon in preoperative period and PON1 activity towards phenyl acetate in seventh stage of experiment tended to inversely correlate with the occurrence of postoperative complications.

Conclusion

The paraoxonase 1 plasma activity is markedly reduced during CABG surgery.
Literature
1.
2.
Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481–8.CrossRefPubMed
3.
Mackness B, Arrol S, Durrington PN, et al. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152–4.CrossRefPubMed
4.
Mackness B, Quarck R, Verreth W, et al. Human paraoxonase −1 overexpression inhibits atherosclerosis in a mouse model of a metabolic syndrome. Arteriosc Thromb Vasc Biol. 2006;26:1545–50.CrossRef
5.
Guns PJ, Van Assche T, Verreth W, et al. Paraoxonase 1 gene transfer lower vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice wit preexisting atherosclerosis. Br J Pharmacol. 2008;153:508–16.CrossRefPubMed
6.
Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284–7.CrossRefPubMed
7.
Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation. 2000;101:2510–7.CrossRefPubMed
8.
Bayrak A, Bayrak T, Bodur E, et al. The effect of HDL bound and free PON1 on copper induced LDL oxidation. Chem Biol Interact. 2016;257:141–6.CrossRefPubMed
9.
Mackness B, Durrington P, McElduff P, et al. Low paraoxonase1 activity predicts coronary events in the Caerphilly prospective study. Circulation. 2003;107:2775–9.CrossRefPubMed
10.
Durmaz T, Keles T, Ayhan H, et al. Diminished serum paraoxonase activity in patients with coronary artery calcification. Kardiol Pol. 2014;72:831–838.
11.
Ikeda Y, Inoue M, Suehiro T, et al. Low human paraoxonase predicts cardiovascular events in Japanese patiets with type 2 diabetes. Acta Diabetol. 2009;46:239–42.CrossRefPubMed
12.
van Himbergen TM, van der Schouw YT, Voorbij HAM, et al. Paraoxonase1 (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis. 2008;198:408–14.CrossRef
13.
Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19:330–5.CrossRefPubMed
14.
Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardio- th Surg. 2002;21:232–44.CrossRef
15.
Michel P, Roques F, Nashef SA. The Euroscore project group: logistic and additive euro SCORE for high risk patients. Eur J Cardiothorac Surg. 2003;23:684–7.CrossRefPubMed
16.
Eckerson H, Romson WJ, Wyte C, La Du B. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 1983;35:214–27.PubMedPubMedCentral
17.
LaDu BN. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. p. 51–91.
18.
Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site is required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase Q and R. Arterioscer Thromb Vasc Biol. 1998;18:1617–24.CrossRef
19.
Davies HG, Richter RJ, Keifer M, et al. The effects of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996;14:334–6.CrossRefPubMed
20.
Sanghera DK, Saha N, Aston CE, et al. DNA polymorphism in two paraoxonase genes (PON1 and PON2) are associated with the risk od coronary heart disease. Am J Hum Genet. 1998;314:410–8.
21.
Ombres D, Pannitteri G, Moutali A, et al. The Gln–Arg 192 polymorphism of the human paraoxonase gene is not associated with the coronary heart disease in Italian patients. Arterioscler Thromb Vasc Biol. 1998;18:1611–6.CrossRefPubMed
22.
Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease. J Clin Invest. 1995;96:3005–8.CrossRefPubMedPubMedCentral
23.
Anitkainen M, Muromtki S, Syvnne M, et al. The Gln–Arg 192 polymorphism of the human paraoxonase gene is not associated with the risk of coronary heart disease in Finns. J Clin Invest. 1996;191:883–5.CrossRef
24.
Mackness B, Mackness MI, Arrol S, et al. Effects of the molecular polymorphism of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997;122:265–8.CrossRefPubMedPubMedCentral
25.
Suehiro T, Nakamura T, Inoue M, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis. 2000;150:295–8.CrossRefPubMed
26.
Deakin S, Leviev I, Brulhart Meynet MC, et al. Paraoxonase −1 promoter haplotypes and serum paraoxonase: a predominant role in vivo for polymorphic position −107 implicating the transcription factor Sp1. Biochem J. 2003;372:643–9.CrossRefPubMedPubMedCentral
27.
Wysocka A, Cybulski M, Berbeć H, et al. Prognostic value of paraoxonase 1 in patients undergoing coronary artery bypass grafting surgery. Med Sci Monit. 2014;20:594–600.CrossRefPubMedPubMedCentral
28.
Mackness B, Turkie W, Mackness M. Paraoxonase −1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease. Arch Med Sci. 2013;1:8–13.CrossRef
29.
Matata BM, Sosnowski AW, Galinanes M. Off-pump bypass graft operation significantly reduces oxidative stress and inflammation. Ann Thorac Surg. 2000;69:785–91.CrossRefPubMed
30.
31.
Kunt AS, Selek S, Celik H, et al. Decrease of total antioxidant capacity during coronary artery bypass surgery. Mt Sinai J Med. 2006;73:777–83.PubMed
32.
Hatemi AC, Ceviker K, Togut A, et al. Oxidant status following cardiac surgery with phosphorylcholine-coated extracorporeal circulation systems. Oxidative Med Cell Longev. 2016;2016:3932092.CrossRef
33.
Das, Vasisht Nm Das L et al: Correlation between total antioxidant staus and lipid peroxidation in hypercholesterolemia. Current Science. 2000;78:486–487,
34.
Luyten CR, van Overveld FJ, De Backer LA, et al. Antioxidant defence during cardiopulmonary bypass surgery. Eur J Cardiothorac Surg. 2005;27:611–6.CrossRefPubMed
35.
Maxkness B, Hunt R, Durrington PN. Mackness MI: ncreased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1233–8.CrossRef
36.
Arrol S, Mackness MI, Durrington PN. High-density lipoprotein associated enzymes and the prevention of low-density lipoprotein oxidation. Eur J Lab Med. 1996;4:33–8.
37.
Sato M, Ohkawa R, Yoshimoto A. Effects of serum amyloid a on the structure and antioxidant ability of high density lipoprotein. Biosci Rep. 2016;36 doi:10.​1042/​BRS20160075.
38.
Kumaraswamy SB, Linder A, Akresson P, et al. Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes. Crit Care. 2012;16:R60.CrossRefPubMedPubMedCentral
39.
Mackness B, Durrington PN, Mackness MI. Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Commun. 1998;247:443–6.CrossRefPubMed
40.
Kunnen S, Van Eck M. Lecithin: cholesterol acyltransferase: old friend or foe in atheroclerosis? J Lipid Res. 2012;53(1783):1799.
41.
Fan J, Watanabe T. Inflammatory reactions in the patogenesis of atherosclerosis. J Atheroscler Thromb. 2003;10:63–71.CrossRefPubMed
42.
Mattila KJ, Valtonen VV, Nieminen M, et al. Dental infection and the risk of new coronary events: prospective study of patients with documented coronary artery disease. Clin Infect Dis. 1995;20:588–92.CrossRefPubMed
43.
Momiyama Y, Ohmori R, Taniguchi H, et al. Association of Mycoplasma pneumoniae infection with coronary artery disease ant its interaction with chlamydial infection. Atherosclerosis. 2004;176:139–44.CrossRefPubMed
44.
Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758–67.CrossRefPubMedPubMedCentral
45.
Kumon Y, Nakauchi Y, Kidawara K, et al. A longitudinal analysis of alteration in lecithin-cholesterol acyltransferase and paraoxonase activities following laparoscopic cholecystectomy relative to other parameters of HDL function and the acute phase response. Scand J Immunol. 1998;48:419–24.CrossRefPubMed
46.
47.
Masse L, Antonacci M. Low cardiac output syndrome. Identification and management. Crit Care Nurs Clin North Am. 2005;17:375–83.CrossRefPubMed
48.
Hussain G, Azam H, Raza Baig MA, et al. Early outcomes of on – pump versus off pump coronary artery bypass grafting. Pak J Med Sci. 2016;32:917–21.PubMedPubMedCentral
49.
WenJun D. Qiang Ji, YunQing Shi et al: predictors of low cardiac out put syndrome after isolated coronary artery bypass grafting. Int Heart J. 2015;56:144–9.CrossRef
50.
Chaudhry UA, Harling L, Sepehripor AH, et al. Beating – heart versus conventional on – pump coronary artery bypass grafting; meta – analysis of clinical outcomes. Ann Thorac Surg. 2015;100:2251–60.CrossRefPubMed
51.
Lamy A, Devereaux PJ, Prabhakran D, et al. Off – pump or on pump coronary – artery bypass graffting at 30 days. N Engl J Med. 2012;366:1489–97.CrossRefPubMed
52.
Zhang J, Lang Y, Guo L, et al. Preventive use of intra-aortic baloon pump in patients undergoing high risk coronary artery bypass grafting: a retrospective study. Med Sci Monit. 2015;21:855–60.CrossRefPubMedPubMedCentral
53.
Plicner D, Stoliński J, Wąsowicz M, et al. Preoperative values of inflammatory markers predicts clinical outcomes in patients after CABG regardless of the use of cardiopulmonary bypass. Indian Heart J. 2016;68:S10–5.CrossRefPubMed
54.
Bhamidipati CM, LaPar DJ, Mehta GV, et al. Albumin is a better predictor of outcomes than body mass index following coronary artery bypass grafting. Surgery. 2011;150:626–34.CrossRefPubMedPubMedCentral
55.
Storti S, Cerillo AG, Rizza A, et al. Coronary artery bypass grafting surgery is associated with a marked reduction in serum homocysteine and folate levels in the early postoperative period. Eur J Cardiothorac Surg. 2004;26:682–6.CrossRefPubMed
Metadata
Title
Dynamic changes of paraoxonase 1 activity towards paroxon and phenyl acetate during coronary artery surgery
Authors
Anna Wysocka
Marek Cybulski
Henryk Berbeć
Andrzej Wysokiński
Janusz Stążka
Jadwiga Daniluk
Tomasz Zapolski
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2017
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-017-0528-z

Other articles of this Issue 1/2017

BMC Cardiovascular Disorders 1/2017 Go to the issue

Study protocol

Feasibility and safety of early discharge after transfemoral transcatheter aortic valve implantation – rationale and design of the FAST-TAVI registry

Research article

Advanced glycation end products in children with type 1 diabetes and early reduced diastolic heart function

Research article

The Relationship between Pulse Wave Velocity and Coronary Artery Stenosis and Percutaneous Coronary Intervention: a retrospective observational study

Research article

Exploration of the methodological quality and clinical usefulness of a cross-sectional sample of published guidance about exercise training and physical activity for the secondary prevention of coronary heart disease

Research article

Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria

Research article

Left ventricular longitudinal function assessment in rabbits after acute occlusion of left anterior descending coronary artery by two-dimensional speckle tracking imaging

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits